Rothschild & Co Redburn analyst Jamie Clark lowered the firm’s price target on Iqvia (IQV) to $214 from $228 and keeps a Buy rating on the shares. The firm says the company offers the lowest risk in the life science group with its contract research organization business having shown more resilience than peer Icon’s over the past 12 months and its technology and analytics segment providing diversification.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV: